Loading…
HCWB
HCW Biologics Inc.
NASDAQ· Healthcare· Biotechnology· CUSIP 40423R303
$3.43+8.20%Price as of Aug 29, 18:44 UTC · updated once a day, after the close
Key metrics
- Market cap
- $6.3M
- P/E
- —
- Forward P/E
- —
- P/B
- 0.7x
- Dividend yield
- —
- Payout
- —
- EPS
- -$16.62
- ROE
- -151.36%
- Profit margin
- -83.05%
- Revenue growth
- +1969.70%
- Beta
- 2.36
- 52-week high
- $36.65
- 52-week low
- $1.50
History
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Investors holding this
Major managers that reported this stock in their latest 13F.
Price over time
▼ -99.8% over 5Y.
today you would have $2.52▼ -99.7%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $5.83 | $107.04 | $294.00 | $459.60 | |
| P/S | 12.9x | 58.7x | 7.7x | 15.5x | 10.2x |
| P/B | 1.8x | 1.2x | — | 3.3x | 1.8x |
| EPS | -$63.78 | -$184.80 | -$168.00 | -$100.80 | |
| Profit margin | -1024.61% | -14677.14% |
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| SNOASonoma Pharmaceuticals, Inc. | $1.31 | — | 0.8x | — | -42.52% | $6.27M |
| ACXPAcurx Pharmaceuticals, Inc. | $1.44 | — | 0.8x | — | -128.11% | $6.19M |
| ENVBEnveric Biosciences, Inc. | $1.37 | — | 0.3x | — | -170.04% | $6.13M |
| VNRXVolitionrx Ltd | $0.45 |
About the company
HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and diseases in the United States. Its lead products include HCW11-018b, a novel, tetra-valent T-Cell engager; HCW11-040, a multifunctional fusion molecule that is a combination of cytokines and pembrolizumab; and HCW9302, injectable and interleukin 2 (IL-2) fusion protein complex, which is in clinical trial in patients with alopecia areata diseases. The company also develops HCW9201, a fusion protein designed as a reagent to use in the production of natural killer (NK) cell-based therapies; HCW9206, a fusion protein designed as a reagent to use in the production of CAR-therapies for the treatment of infectious diseases; and HCW11-006, a multi-functional immune cell stimulator. It has a license agreement with Wugen Inc. to develop cell therapy-based treatments; and a license, research and co-development agreement with WY Biotech Co., Ltd. for its preclinical molecule. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.
- 35
- Miramar, United States
Company description provided by Yahoo Finance.